

Substitute for form 1449/PTO

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**Complete if Known**

Application Number	10/672,724
Filing Date	9/25/2003
First Named Inventor	Robinson et al.
Art Unit	1617
Examiner Name	Wang
Attorney Docket Number	UCI-12094

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

[illegible]

Examiner Signature	<i>Carlee Stuyck</i>	Date Considered	4/18/07
-----------------------	----------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/672,724
Filing Date	9/25/2003
First Named Inventor	Robinson et al.
Art Unit	1617
Examiner Name	Wang
Attorney Docket Number	UCI-12094

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CH	4	Robinson et al., "Inhibitors of HIV-1 replication that inhibit HIV integrase," PNAS 93:6326-6331 (1996)	
CH	5	Deeks et al., "HIV-1 Protease Inhibitors," JAMA 277:145-153 (1997)	
CH	6	Konig et al., "The Caffeyolys as a New Family of Natural Antiviral Compounds," Naturwissenschaften 72:659-661 (1985)	
CH	7	King et al., "Resistance to the Anti-Human Immunodeficiency Virus Type 1 Compounds L-Chicoric Acid Results from a Single Mutation at Amino Acid 140 of Integrase," J. of Virology 72:8420-8424 (1998)	
CH	8	King et al., "Structure-Activity Relationships: Analogues of the Dicafeoylquinic and Dicafeoyltartaric Acids as Potent Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and Replication, J. Med. Chem. 42:497-509 (1999)	
CH	9	Stames et al., "Cellular Metabolism of 2',3'-Dideoxycytidine, a Compounds Active against Human Immunodeficiency Virus in Vitro," J. Biol Chem. 262:988-991 (1987)	
CH	10	Robinson, Jr., "L-Chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350)," Antiviral Res. 39:101-111 (1998)	
CH	11	McDougall et al., "Dicafeoylquinic and Dicafeoyltartaric Acids Are Selective Inhibitors of Human Immunodeficiency Virus Type 1 Integrase," Antimicrobial Agents and Chemotherapy 42:140-146 (1998)	
CH	12	Beale et al., "Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1," Antiviral Res. 45:223-232 (2000)	
CH	13	Farnet et al., "Human Immunodeficiency Virus Type 1 cDNA Integration: New Aromatic Hydroxylated Inhibitors and Studies of the Inhibition Mechanism," Antimicrobial Agents and Chemotherapy 42:224502253 (1998)	

Examiner Signature	<i>Calvin Stuyck</i>	Date Considered	4/18/07
--------------------	----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.